Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

What's the Difference? Sepracor's Xopenex Hit Hard by Coverage Cut

This article was originally published in RPM Report

Executive Summary

Xopenex reimbursement is being slashed by Medicare. The message: CMS wants proof of differentiation before it will pay more for line extensions and new formulations. That means trouble ahead for a lot of other products.

You may also be interested in...



Defining Line Extensions: Medicaid Rebate Change Gives CMS Power to take a Bite Out of Lifecycle Management

A new provision in the health care reform law means that new formulations of oral brand name drugs will be subject to additional rebates. But who is affected depends in part on how CMS defines a line extension.

Defining Line Extensions: Medicaid Rebate Change Gives CMS Power to take a Bite Out of Lifecycle Management

A new provision in the health care reform law means that new formulations of oral brand name drugs will be subject to additional rebates. But who is affected depends in part on how CMS defines a line extension.

Taking on CMS

Amgen and J&J have billions of dollars at stake in the battle to convince CMS to change its coverage proposal for EPO in cancer patients. Win or lose, their efforts will be a valuable case study for any other manufacturer that fi nds itself facing an adverse reimbursement policy.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

PS080318

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel